Please login to the form below

Not currently logged in

Regeneron's bispecific for lymphoma works in CAR-T failures


Regeneron has reported positive results with its REGN1979 drug in patients with non-Hodgkin’s lymphoma, including the evidence it can work in patients who have previously tried CAR-T therapies.

The new data for the highly-touted bispecific antibody – which targets both CD20 and CD3 – was presented at the European Haematology Association (EHA) congress in Amsterdam and showed very high response rates in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

Overall, REGN1979 achieved a response in 13 of 14 FL patients (93%), with 10 of them (71%) having a complete response. Regeneron also reported a 57% overall response rate in DLBCL – four out of seven patients – which were all complete responses.

There were two responses among four patients who were treated with the bispecific drug after having progressed despite therapy with CAR-T for DLBCL.

At the moment, Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) are the CAR-Ts that have been approved to treat DLBCL, with pivotal trials showing that they can achieve a response in around 50% of patients. That still leaves a large proportion of non-responders and patients who go on to relapse who could benefit from having another treatment option.

“In this trial, two patients who failed CAR-T therapy and received REGN1979 … achieved complete responses; there is currently no approved therapy for patients who progress on CAR-Ts,” commented Israel Lowy, Regeneron’s head of clinical and translational sciences.

The biotech is now moving ahead with a phase 2 programme that could potentially support regulatory filings for REGN1979 and will get underway this month in indolent and aggressive NHL types.

Meanwhile, Regeneron wants to develop REGN1979 for first-line use in these forms of lymphoma as well, positioning the drug as an alternative to CAR-T which can have serious side effects and can take some time to implement given the complexity of the cell-based treatment procedure.

REGN1979 is in a race to market with a rival CD20/CD3 bispecific antibody being developed by Roche.

Roche’s mosunetuzumab candidate showed activity in relapsed/refractory B-cell indolent and aggressive NHL in a phase 1/2 trial reported at the American Society of Haematology (ASH) meeting last December, with a 69% overall response /39% complete response rate in FL, although the numbers looked less impressive in DLBCL with rates of 34% and 19%, respectively.

Article by
Phil Taylor

17th June 2019

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
Senior Analytics Specialist joins Research Partnership...
Digital technologies: Pharma’s answer to achieving net zero emissions?